Rosetta Genomics last week announced that it has regained the US market rights to its three flagship cancer diagnostics, settling a nearly six-month dispute with one-time partner Prometheus Laboratories.

In exchange, Rosetta will pay Prometheus $3.1 million over the next year and a half.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.